Scinovex
articleTop 10% cited

A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

Thrombosis and Haemostasis · 1993 · Vol. 69(03) · pp. 236–239
F.R. RosendaalSuzanne C. CannegieterF.J.M. van der MeerE Briët

Abstract

Oral anticoagulant therapy has been shown to be effective for several indications. The optimal intensity of anticoagulation for each indication, however, is largely unknown. To determine this optimal intensity, randomised clinical trials are conducted in which two target levels of anticoagulation are compared. This approach is inefficient, since the choice of the target levels will be arbitrary. Moreover, the achieved intensity is not taken into account. We propose a method to determine the optimal achieved intensity of anticoagulation. This method can be applied within a clinical trial as an "efficacy-analysis", but also on data gathered in day-to-day patient care. In this method, INR-specific incidence rates of events, either thromboembolic or hemorrhagic, are calculated. The numerator of the incidence rate is based on data on the INR at the time of the event. The denominator consists of the person-time at each INR value, summed over all patients, and is calculated from all INR measurements of all patients during the follow-up interval. This INR-specific person-time is calculated with the assumption of a linear increase or decrease between two consecutive INR determinations. Since the incidence rates may be substratified on covariates, efficient assessment of the effects of other factors (e.g. age, sex, comedication) by multivariate regression analysis becomes possible. This method allows the determination of the optimal pharmacological effects of anticoagulation, which can form a rational starting point for choosing the target levels in subsequent clinical trials.

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAntiplatelet Therapy and Cardiovascular DiseasesMedicineIntensity (physics)Incidence (geometry)CovariateClinical trialOral anticoagulantAnticoagulantLinear regressionConfidence intervalStatistics

MeSH terms

Administration, OralAnticoagulantsFollow-Up StudiesHemorrhageHumansProbabilityProthrombin TimeResearch DesignRisk FactorsThromboembolismIncidenceRandomized Controlled Trials as Topic
Citations
2,047
FWCI
4.99
field-weighted impact
References
7
Percentile
96%
vs. same field & year
Citations per year
Cited by
Antithrombotic Therapy for Atrial Fibrillation
CHEST Journal · 2018 · 924 citations
The Pharmacology and Management of the Vitamin K Antagonists
CHEST Journal · 2004 · 1,533 citations
Oral Anticoagulant Therapy
CHEST Journal · 2012 · 1,489 citations
Pharmacology and Management of the Vitamin K Antagonists
CHEST Journal · 2008 · 2,096 citations
Apixaban versus Warfarin in Patients with Atrial Fibrillation
New England Journal of Medicine · 2011 · 8,827 citations
Guidelines on oral anticoagulation (warfarin): third edition – 2005 update
British Journal of Haematology · 2005 · 393 citations
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
New England Journal of Medicine · 2009 · 11,130 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.